Publications
1. Am Heart J 2004 Jul; 148(1):52-61 – Teo lead
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET / TRANSCEND) Trials July 2004
2. J Int Med Res 2005; 33 Suppl 1: 50A-57A – Anderson lead
Rationale and Design of the Cardiac Magnetic Resonance Imaging Substudy of The ONTARGET Trial Programme 2005
3. Circulation. 2007 Mar 20; 115(11):1371-5 – Held lead
Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk March 20, 2007
4. Am Heart J 2007 Jul; 154(1):94-101 – Böhm lead
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessemNT Study in ACE-Intolerant Subjects with Cardiovascular Disease (ONTARGET / TRANSCEND) July 2007
5. Vas Health Risk Manag 2007:3(4) 381-387 - Topouchian lead
Arterial Stiffness and Pharmacological Interventions – The Transcend Arterial stiffness Substudy (TRANS study) October 2007
6. N Engl J Med Apr 10;358(15)”1547-59 – Yusuf lead
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events April 10, 2008
7. Lancet 2008 Aug 16;372(9638):547-53 – Mann lead
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. August 16, 2008
8. Lancet 2008; 372: 1174-83
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial September 27, 2008
9. Diabetes Res Clin Pract 2009; 83(3):387-93 – Cukierman-Yaffe lead
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET / TRANSCEND Research Programme March 2009
10. Ann Intern Med. 2009 Jul 7;151(1):1-10, w1-2 – Mann lead
Effect of Telmisartan on Renal Outcomes: A Randomized Trial July 7, 2009
11. J Hypertens. 2009 Jul; 27(7):1360-9 – Sleight lead
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study July 7, 2009
12. Clin Res Cardiol. 2009 Jul;98(7):421-33 – Cowan lead
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial / telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics July 7, 2009